

# Catastrophic Antiphospholipid Syndrome Market to Reach \$6.17 Billion by 2029 with 10.3% CAGR

The Business Research Company's Catastrophic Antiphospholipid Syndrome Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED
KINGDOM, August 20, 2025
/EINPresswire.com/ -- Get 30% Off All
Global Market Reports With Code
ONLINE30 – Stay Ahead Of Trade Shifts,
Macroeconomic Trends, And Industry Disruptors



What Is The Catastrophic Antiphospholipid Syndrome Market Size And Growth?

The market size for the devastating antiphospholipid syndrome has been expanding swiftly in



Get 30% Off All Global
Market Reports With Code
ONLINE30 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors"
The Business Research
Company

the past few years. It is projected to surge from \$3.76 billion in 2024 to \$4.16 billion in 2025 with a 10.7% compound annual growth rate (CAGR). The exceptional growth during the historic period can be credited to increasing implementation of plasmapheresis and intravenous immunoglobulin (IVIG), enhanced access to biologics and monoclonal antibodies, escalating patient supports initiatives and advocacy for rare diseases, the rise in clinical trials aimed at specific therapies, and expansion in healthcare expenditure.

The market size for catastrophic antiphospholipid syndrome is predicted to experience considerable expansion in the upcoming years, escalating to a valuation of \$6.17 billion by 2029, with a compound annual growth rate of 10.4%. The surge throughout the projected period can be associated with the growing prevalence of autoimmune disorders, heightened awareness amongst healthcare specialists, increased application of immunosuppressive treatments, a rise in thrombosis-related complications, and an escalating demand for high-end diagnosis tools. In the prediction timeline, the critical trends expected are enhancements in the detection

technology for autoantibodies, the creation of instant diagnostic instruments, the incorporation of artificial intelligence in clinical decision-making aids, tech-based innovations in immunoassay platforms, and the formulation of specific biologics and monoclonal antibodies.

Download a free sample of the catastrophic antiphospholipid syndrome market report: <a href="https://www.thebusinessresearchcompany.com/sample.aspx?id=25718&type=smp">https://www.thebusinessresearchcompany.com/sample.aspx?id=25718&type=smp</a>

What Are The Current Leading Growth Drivers For Catastrophic Antiphospholipid Syndrome Market?

The catastrophic antiphospholipid syndrome market is expected to grow due to the increasing occurrence of autoimmune disorders. These disorders involve an overactive immune response that damages the body's own cells and tissues. The rise in these conditions can be partially attributed to the higher levels of exposure to environmental toxins, which interfere with the immune system and trigger abnormal immune reactions. Such disorders contribute to catastrophic antiphospholipid syndrome by producing antiphospholipid antibodies, leading to widespread blood clotting and failure of multiple organs. The Crohn's and Colitis Foundation of Canada, for instance, reported in June 2023 that Canada had 322,600 people living with inflammatory bowel disease in 2023, with projections of this figure rising to 470,000 by 2035 and annual new cases growing from 11,000 to 14,000. As such, the growth of the catastrophic antiphospholipid syndrome market is being fuelled by the rising prevalence of autoimmune disorders. In addition, the catastrophic antiphospholipid syndrome market is anticipated to expand due to a rise in healthcare spending. This expenditure refers to the total amount of funds directed towards health services, goods, and public health activities by individuals, governments, and organisations. With healthcare spending witnessing an uptick due to an ageing population that requires more regular and intensive medical services, the access to advanced treatments, such as intensive care, anticoagulation therapy, immunosuppressants, and plasmapheresis for patients suffering from catastrophic antiphospholipid syndrome has increased. For instance, provisional data from the UK's Office for National Statistics in May 2023 show that in 2022, UK healthcare expenditure stood at around \$331.70 billion (£283 billion), which represents a nominal hike of 0.7% compared to 2021. As such, the growth of the catastrophic antiphospholipid syndrome market is being driven by the boost in healthcare spending.

Which Companies Are Currently Leading In The Catastrophic Antiphospholipid Syndrome Market?

Major players in the Catastrophic Antiphospholipid Syndrome Global Market Report 2025 include:

- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company

- AstraZeneca PLC.
- Abbott Laboratories
- Novartis AG.
- Fresenius Kabi AG.

## How Is The Catastrophic Antiphospholipid Syndrome Market Segmented?

The catastrophic antiphospholipid syndrome market covered in this report is segmented -

- 1) By Treatment: Anticoagulants, Immunosuppressive Therapy, Plasma Exchange Therapy (Plasmapheresis), Intravenous Immunoglobulin (IVIG), Other Treatments
- 2) By Route Of Administration: Oral, Parenteral
- 3) By Diagnostic Tools: Blood Testing, Imaging Techniques, Genetic Testing
- 4) By End-User: Hospitals, Specialty clinics, Ambulatory surgical centers, Other End-Users

### Subsegments:

- 1) By Anticoagulants: Heparin, Low Molecular Weight Heparin (LMWH), Warfarin, Direct Oral Anticoagulants (DOACs), Fondaparinux
- 2) By Immunosuppressive Therapy: Corticosteroids, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil, Methotrexate
- 3) By Plasma Exchange Therapy (Plasmapheresis): Therapeutic Plasma Exchange (Tpe), Double Filtration Plasmapheresis (Dfpp), Centrifugal Plasmapheresis, Membrane-Based Plasmapheresis
- 4) By Intravenous Immunoglobulin (Ivig): Standard Intravenous Immunoglobulin (Ivig), High-Dose Intravenous Immunoglobulin (Ivig), Liquid Intravenous Immunoglobulin (Ivig), Lyophilized Intravenous Immunoglobulin (Ivig)
- 5) By Other Treatments: Monoclonal Antibodies, Complement Inhibitors, Antiplatelet Agents, Anti-Tumor Necrosis Factor (Tnf) Agents, Organ Support Therapies

View the full catastrophic antiphospholipid syndrome market report: <a href="https://www.thebusinessresearchcompany.com/report/catastrophic-antiphospholipid-syndrome-global-market-report">https://www.thebusinessresearchcompany.com/report/catastrophic-antiphospholipid-syndrome-global-market-report</a>

Which Is The Dominating Region For The Catastrophic Antiphospholipid Syndrome Market? In 2024, North America held the leading position in the global market for catastrophic antiphospholipid syndrome. However, the highest growth rate during the forecast period is predicted to be seen in the Asia-Pacific region. The regions analyzed in the global market report for catastrophic antiphospholipid syndrome include North America, Western Europe, Eastern Europe, Asia-Pacific, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Catastrophic Antiphospholipid Syndrome Market 2025, By <u>The Business Research Company</u>

Antiphospholipid Syndrome Treatment Global Market Report 2025 <a href="https://www.thebusinessresearchcompany.com/report/antiphospholipid-syndrome-treatment-">https://www.thebusinessresearchcompany.com/report/antiphospholipid-syndrome-treatment-</a>

# global-market-report

Lecithin And Phospholipids Global Market Report 2025 <a href="https://www.thebusinessresearchcompany.com/report/lecithin-and-phospholipids-global-market-report">https://www.thebusinessresearchcompany.com/report/lecithin-and-phospholipids-global-market-report</a>

Hypolipidemics Global Market Report 2025 <a href="https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report">https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report</a>

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

### Follow Us On:

• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/841403497

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.